Kaposi sarcoma (KS) is a rare cancer with an unusual backstory. Unlike many cancers, it has a clearly identified viral partner: human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma-associated herpesvirus (KSHV). Yet carrying the virus does not mean someone will develop cancer. In most healthy people, the immune system keeps HHV-8 under control without any drama. Trouble is more likely when immune defenses become weakened.
Kaposi sarcoma most often causes red, purple, brown, or bluish lesions on the skin or inside the mouth. It can also involve lymph nodes and internal organs, including the lungs and digestive tract. The disease became widely recognized during the HIV/AIDS epidemic, although HIV-associated KS is only one form of the condition.
Today, effective HIV treatment has dramatically changed the outlook for many people with HIV-associated Kaposi sarcoma. Other forms may progress slowly for years or require treatment depending on where the lesions occur and how extensively the disease has spread.
What Is Kaposi Sarcoma?
Kaposi sarcoma is a cancer that develops from cells associated with blood vessels and lymphatic vessels. Its lesions contain abnormal spindle-shaped cells, newly formed blood vessels, inflammatory cells, and blood cells. That rich blood-vessel network helps explain why the spots can have their characteristic reddish, purple, or brown appearance.
KS is different from a typical cancer that begins as one lump and later spreads elsewhere. Lesions may develop at several locations around the same time. They can appear on the skin, mucous membranes, lymph nodes, gastrointestinal tract, lungs, or other tissues.
Doctors commonly describe four main clinical forms of Kaposi sarcoma.
HIV-Associated or Epidemic Kaposi Sarcoma
This form occurs in people living with HIV who are also infected with HHV-8. It became especially prominent during the early years of the AIDS epidemic, when effective antiretroviral therapy was not available.
Modern antiretroviral therapy has made HIV-associated KS much less common in the United States. Keeping HIV suppressed and allowing the immune system to recover can sometimes cause KS lesions to shrink without separate cancer chemotherapy.
Classic Kaposi Sarcoma
Classic KS typically occurs in older adults, particularly men with Mediterranean, Eastern European, or Middle Eastern ancestry. It often progresses slowly and commonly begins with lesions on the feet or lower legs.
Some people may live with localized classic KS for many years. Treatment is generally based on symptoms, progression, swelling, lesion location, and the effect of the disease on quality of life.
Endemic Kaposi Sarcoma
Endemic KS occurs primarily in parts of sub-Saharan Africa, where HHV-8 infection is more common. Clinical behavior varies considerably. Some cases resemble slow-growing classic KS, while others can be aggressive and involve lymph nodes or internal organs.
Transplant-Associated Kaposi Sarcoma
Organ transplant recipients usually take medications that suppress immune activity so their bodies do not reject the transplanted organ. Unfortunately, that necessary immune suppression can also give HHV-8 an opportunity to promote Kaposi sarcoma.
Treatment may involve carefully reducing or changing immunosuppressive medication under supervision of the transplant and cancer teams. This is definitely not a do-it-yourself medication-adjustment situation.
What Causes Kaposi Sarcoma?
Infection with HHV-8/KSHV is necessary for Kaposi sarcoma to develop. The virus infects cells and produces changes that can encourage abnormal cell survival, inflammation, and new blood-vessel formation.
However, HHV-8 infection alone usually does not cause KS. Many infected people never develop the cancer because their immune systems successfully control the virus.
The risk increases substantially when immune surveillance becomes impaired. HIV infection is one important example, especially when HIV is untreated and CD4 cell levels are low. Long-term immune-suppressing treatment after organ transplantation is another.
How Does HHV-8 Spread?
Scientists continue to study exactly how HHV-8 moves between people. Transmission patterns vary among populations, but saliva appears to play an important role, and sexual transmission can occur. The virus can also sometimes be transmitted through blood or from parent to child.
Having HHV-8 does not mean someone has HIV. They are completely different viruses. HIV matters because severe HIV-related immune suppression makes it much easier for HHV-8-associated disease to develop.
Who Is at Higher Risk?
Because HHV-8 infection is required, exposure to the virus is the starting point. Among infected people, factors associated with a higher chance of developing Kaposi sarcoma include:
- Untreated or poorly controlled HIV infection.
- Low CD4 immune cell counts in people living with HIV.
- Long-term immunosuppressive treatment following organ transplantation.
- Older age in people susceptible to classic KS.
- Living in regions where HHV-8 is relatively common.
- Certain geographic or ancestral backgrounds associated with classic or endemic disease.
The important distinction is between having a risk factor and having cancer. Even among people infected with HHV-8, most do not automatically develop Kaposi sarcoma.
Kaposi Sarcoma Symptoms
Skin Lesions
The most recognizable Kaposi sarcoma symptom is an abnormal skin lesion. Lesions may be:
- Pink, red, purple, blue-brown, or dark brown.
- Flat patches.
- Slightly raised plaques.
- Firm bumps or nodules.
- Single or multiple.
They commonly appear on the legs, feet, face, or other areas of skin. Skin tone affects how lesions look, so KS does not always resemble the textbook photograph someone finds during a 2 a.m. internet search.
Lesions are often painless. However, extensive disease around the feet, legs, or groin can interfere with lymphatic drainage and produce significant swelling, known as lymphedema. The swelling itself may become uncomfortable or make walking difficult.
Lesions in the Mouth
Kaposi sarcoma can develop inside the mouth, particularly on the palate or gums. Small lesions may cause few symptoms, while larger lesions can interfere with eating, speaking, swallowing, or dental health.
Digestive Tract Symptoms
KS lesions can occur in the stomach or intestines. Many gastrointestinal lesions produce no obvious symptoms, but more extensive involvement may lead to abdominal discomfort, nausea, diarrhea, anemia, or gastrointestinal bleeding.
Lung Symptoms
Pulmonary Kaposi sarcoma is more serious. Possible symptoms include shortness of breath, cough, chest discomfort, or reduced oxygen levels. Respiratory symptoms in someone at risk for KS need careful evaluation because infections and other lung diseases can produce similar problems.
When Should a Skin Lesion Be Checked?
A purple or brown spot does not automatically mean Kaposi sarcoma. Bruises, vascular growths, infections, inflammatory conditions, and several other skin disorders can resemble it.
Still, a new lesion that persists, grows, multiplies, bleeds, or occurs in someone with HIV or immune suppression deserves medical attention. A clinician should also evaluate unexplained persistent leg swelling or respiratory or gastrointestinal symptoms.
How Is Kaposi Sarcoma Diagnosed?
A healthcare professional may suspect KS based on the appearance of the lesions and a person’s medical history, but appearance alone is not enough for a definitive diagnosis.
Skin Biopsy
A biopsy is the key diagnostic test. A small tissue sample is removed and examined by a pathologist under a microscope. Specialized testing can identify proteins associated with HHV-8 in tumor cells and help confirm the diagnosis.
Checking for Internal Disease
Once KS has been diagnosed, additional testing depends on symptoms and the extent of visible disease. Doctors may use blood tests, imaging, endoscopy, bronchoscopy, or other procedures when internal involvement is suspected.
For a person with HIV, evaluation also commonly includes the HIV viral load and CD4 count because immune status helps guide both treatment and prognosis.
How Is Kaposi Sarcoma Treated?
There is no single treatment plan that fits every case. A person with two small skin lesions and excellent immune function has very different needs from someone with rapidly progressing disease involving the lungs.
Treatment therefore depends on the type of KS, number and location of lesions, symptoms, immune status, internal-organ involvement, overall health, and previous therapies.
Antiretroviral Therapy for HIV-Associated KS
For people with HIV, starting or optimizing antiretroviral therapy (ART) is a cornerstone of treatment. Suppressing HIV allows immune function to recover, which may significantly reduce KS activity.
People with mild, localized HIV-associated KS may sometimes improve with ART alone. More extensive, symptomatic, or internal-organ disease generally requires cancer treatment in addition to ART.
Local Treatments
When only a small number of troublesome lesions are present, doctors may use treatment directed specifically at those areas. Options can include:
- Minor surgical removal.
- Cryotherapy.
- Radiation therapy.
- Medication injected directly into a lesion.
- Selected topical treatments.
Local treatment can improve discomfort, bleeding, swelling, function, or appearance. It does not necessarily prevent lesions from developing elsewhere because KS can be a multicentric disease.
Radiation Therapy
Kaposi sarcoma is generally sensitive to radiation. Radiation therapy can be useful for localized lesions that cause pain, bleeding, swelling, cosmetic concerns, or problems with everyday activities.
Systemic Chemotherapy
Chemotherapy circulates throughout the body, making it appropriate when KS is widespread, progressing rapidly, causing major swelling, or involving organs such as the lungs or gastrointestinal tract.
Pegylated liposomal doxorubicin is an important first-line systemic treatment for advanced HIV-associated Kaposi sarcoma. Paclitaxel is another active chemotherapy drug and may be used in selected situations, including disease that does not adequately respond to initial therapy.
The specific drug, dose, and treatment schedule need to be individualized by an oncology team because side effects and interactions with other medications matter.
Immunotherapy and Other Medications
Other systemic therapies are available in selected cases. Pomalidomide, for example, has demonstrated activity against KS and has been used in patients with and without HIV.
Researchers are also studying immune checkpoint inhibitors and other targeted approaches. Clinical trials are particularly important for recurrent or treatment-resistant disease because KS is uncommon and some newer strategies still have limited evidence compared with established therapies.
Treatment After an Organ Transplant
For transplant-associated KS, changing immune suppression may be one of the most important strategies. Specialists may reduce immunosuppressive therapy when medically feasible or sometimes switch to a different medication, such as an mTOR inhibitor.
These decisions require coordination because doctors must balance controlling the cancer with protecting the transplanted organ.
Can Kaposi Sarcoma Come Back?
Yes. KS can recur after successful treatment because HHV-8 remains in the body. Recurrence does not necessarily mean that earlier treatment failed. The underlying biology of the virus and immune system means that new lesions can develop later.
Follow-up visits allow healthcare professionals to monitor skin lesions, immune status, symptoms, and treatment effects. People should tell their care teams about new lesions, increasing swelling, unexplained bleeding, breathing difficulties, or other meaningful changes.
Kaposi Sarcoma Prognosis
The outlook varies widely. Classic KS may progress very slowly and remain primarily a skin disease for many years. HIV-associated KS can also be controlled successfully in many people, particularly when HIV is effectively suppressed.
More extensive disease involving internal organs presents a greater challenge. Prognosis depends on factors such as immune function, HIV control when applicable, disease distribution, response to therapy, other illnesses, and overall health.
This is why survival statistics found online should never be treated like a personal countdown clock. Population averages cannot account for an individual’s type of KS, immune status, treatment response, or rapidly improving medical care.
Can Kaposi Sarcoma Be Prevented?
There is currently no routinely used vaccine against HHV-8 and no standard screening program for Kaposi sarcoma in the general population.
For people living with HIV, early diagnosis and consistent antiretroviral therapy are among the most important ways to reduce the risk of HIV-associated KS. Effective ART keeps HIV suppressed and helps preserve immune function.
People taking immune-suppressing medications should attend recommended follow-up appointments and report unusual persistent skin changes. They should never reduce or stop transplant medication on their own.
Living With Kaposi Sarcoma: What the Experience Can Be Like
The experience of Kaposi sarcoma often begins with uncertainty rather than an obvious cancer diagnosis. Someone may first notice what looks like a bruise, blister, discolored patch, or harmless bump. Because early lesions can be painless, it is easy to put off an appointment, particularly when a spot seems more annoying than alarming.
Then comes the biopsy. For many patients, that short procedure provides the first definitive answer. Waiting for pathology results can feel much longer than the calendar suggests, especially when someone has already encountered dramatic historical associations between Kaposi sarcoma and AIDS online.
One important part of modern KS care is understanding that the diagnosis has several possible contexts. A person with classic KS and no HIV may have a completely different medical situation from someone newly diagnosed with advanced HIV. Likewise, a transplant recipient can develop KS because medication intentionally suppresses immune activity. The same tumor name does not mean the same treatment journey.
After diagnosis, appointments can involve several specialists. A dermatologist may manage skin lesions, an oncologist may supervise cancer therapy, and an infectious-disease or HIV specialist may handle antiretroviral treatment. Transplant-associated disease can bring transplant physicians into the conversation as well. It may feel like assembling a medical group chat in which everyone actually needs to read the messages.
For people with mild HIV-associated KS, one surprising experience is that controlling HIV itself can be a major part of controlling the cancer. Lesions may gradually flatten or fade as immune function improves. This process does not happen overnight, so follow-up is important even when no chemotherapy is initially required.
People receiving chemotherapy may notice that treatment goals are often very practical: shrink lesions, control internal disease, improve swelling, stop bleeding, reduce discomfort, and restore normal activities. Treatment response may be judged not only by whether lesions disappear but also by whether raised lesions become flatter, swelling improves, and new spots stop forming.
Visible lesions can create another challenge that laboratory results cannot measure. A lesion on the face, hands, or legs may attract unwanted attention or questions. Some people may also worry that others will automatically associate KS with HIV. That can create anxiety about privacy and stigma even when the person does not have HIV at all.
Supportive care therefore matters. Comfortable footwear may help someone dealing with leg swelling. Nutrition support may become useful when oral or gastrointestinal disease interferes with eating. Cancer teams can also address pain, fatigue, emotional stress, treatment side effects, and concerns about appearance.
Follow-up becomes part of the long-term routine because recurrence is possible. Patients often learn their personal baseline: which older lesions are stable, what treated areas normally look like, and what changes deserve a call to the clinic. Photographs may sometimes help clinicians document visible changes over time.
Perhaps the most useful expectation is that Kaposi sarcoma is not one predictable storyline. Some cases are slow and manageable with limited treatment. Others require intensive systemic therapy. Modern HIV treatment has transformed HIV-associated KS in particular, and specialists now have several local and systemic options when additional treatment is necessary.
The practical goal is not to diagnose every mysterious spot in the bathroom mirror. It is to recognize persistent changes, obtain an accurate diagnosis, identify the form and extent of the disease, and match treatment intensity to what the cancer is actually doing.
Conclusion
Kaposi sarcoma is a rare cancer caused by HHV-8/KSHV that develops most often when conditions allow the virus to escape normal immune control. Its best-known signs are red, purple, brown, or bluish skin lesions, but KS can also affect the mouth, lymph nodes, digestive tract, and lungs.
A biopsy is essential for confirming the diagnosis. From there, treatment is personalized. HIV-associated KS frequently improves when effective antiretroviral therapy restores immune function, while advanced disease may require systemic chemotherapy. Local therapies, radiation, immune-directed treatments, and modification of transplant immunosuppression also have important roles in appropriate cases.
Because KS ranges from slowly progressing skin disease to serious internal-organ involvement, evaluation by clinicians experienced with the condition is important. New or changing lesions should be examined rather than diagnosed from photographs alone.
Note: This article is intended for general educational information and should not replace individualized diagnosis or treatment from a qualified healthcare professional. The medical content was synthesized from current information from the National Cancer Institute, NIH HIV clinical guidelines, American Cancer Society, MedlinePlus, Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, Memorial Sloan Kettering Cancer Center, Merck Manual, Stanford Medicine, Dana-Farber Cancer Institute, and U.S. Department of Veterans Affairs resources.
